Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 149

1.

Development and validation of a microsimulation economic model to evaluate the disease burden associated with smoking and the cost-effectiveness of tobacco control interventions in Latin America.

Pichon-Riviere A, Augustovski F, Bardach A, Colantonio L; Latinclen Tobacco Research Group.

Value Health. 2011 Jul-Aug;14(5 Suppl 1):S51-9. doi: 10.1016/j.jval.2011.05.010.

2.

Cost-effectiveness of varenicline versus bupropion, nicotine-replacement therapy, and unaided cessation in Greece.

Athanasakis K, Igoumenidis M, Karampli E, Vitsou E, Sykara G, Kyriopoulos J.

Clin Ther. 2012 Aug;34(8):1803-14. doi: 10.1016/j.clinthera.2012.07.002. Epub 2012 Jul 20.

PMID:
22818870
3.

Effectiveness and cost-effectiveness of computer and other electronic aids for smoking cessation: a systematic review and network meta-analysis.

Chen YF, Madan J, Welton N, Yahaya I, Aveyard P, Bauld L, Wang D, Fry-Smith A, Munafò MR.

Health Technol Assess. 2012;16(38):1-205, iii-v. doi: 10.3310/hta16380. Review.

4.

The Economic Impact of Smoking and of Reducing Smoking Prevalence: Review of Evidence.

Ekpu VU, Brown AK.

Tob Use Insights. 2015 Jul 14;8:1-35. doi: 10.4137/TUI.S15628. eCollection 2015. Review.

5.

Cost-effectiveness analysis of varenicline versus existing smoking cessation strategies in Central America and the Caribbean using the BENESCO model.

Lutz MA, Lovato P, Cuesta G.

Hosp Pract (1995). 2012 Feb;40(1):24-34. doi: 10.3810/hp.2012.02.945.

PMID:
22406880
6.

Cost effectiveness of full coverage of the medical management of smoking cessation in France.

Chevreul K, Cadier B, Durand-Zaleski I, Chan E, Thomas D.

Tob Control. 2014 May;23(3):223-30. doi: 10.1136/tobaccocontrol-2012-050520. Epub 2012 Nov 29.

PMID:
23197369
9.

The burden of smoking-related diseases in Brazil: mortality, morbidity and costs.

Pinto MT, Pichon-Riviere A, Bardach A.

Cad Saude Publica. 2015 Jun;31(6):1283-97. doi: 10.1590/0102-311X00192013. Epub 2015 Jun 1. English, Portuguese.

10.

Smoking cessation treatment and outcomes patterns simulation: a new framework for evaluating the potential health and economic impact of smoking cessation interventions.

Getsios D, Marton JP, Revankar N, Ward AJ, Willke RJ, Rublee D, Ishak KJ, Xenakis JG.

Pharmacoeconomics. 2013 Sep;31(9):767-80. doi: 10.1007/s40273-013-0070-5.

PMID:
23821436
11.

Economic cost of tobacco use in India, 2004.

John RM, Sung HY, Max W.

Tob Control. 2009 Apr;18(2):138-43. doi: 10.1136/tc.2008.027466. Epub 2009 Jan 8.

12.

Cost-effectiveness of motivational interviewing for smoking cessation and relapse prevention among low-income pregnant women: a randomized controlled trial.

Ruger JP, Weinstein MC, Hammond SK, Kearney MH, Emmons KM.

Value Health. 2008 Mar-Apr;11(2):191-8. Epub 2007 Sep 13.

13.

The long-term cost-effectiveness of varenicline (12-week standard course and 12 + 12-week extended course) vs. other smoking cessation strategies in Canada.

von Wartburg M, Raymond V, Paradis PE.

Int J Clin Pract. 2014 May;68(5):639-46. doi: 10.1111/ijcp.12363. Epub 2014 Jan 29.

PMID:
24472120
14.

Cost Effectiveness of Free Access to Smoking Cessation Treatment in France Considering the Economic Burden of Smoking-Related Diseases.

Cadier B, Durand-Zaleski I, Thomas D, Chevreul K.

PLoS One. 2016 Feb 24;11(2):e0148750. doi: 10.1371/journal.pone.0148750. eCollection 2016.

15.

Health and economic effects from linking bedside and outpatient tobacco cessation services for hospitalized smokers in two large hospitals: study protocol for a randomized controlled trial.

Fellows JL, Mularski R, Waiwaiole L, Funkhouser K, Mitchell J, Arnold K, Luke S.

Trials. 2012 Aug 1;13:129. doi: 10.1186/1745-6215-13-129.

16.

Cost-effectiveness of face-to-face smoking cessation interventions: a dynamic modeling study.

Feenstra TL, Hamberg-van Reenen HH, Hoogenveen RT, Rutten-van Mölken MP.

Value Health. 2005 May-Jun;8(3):178-90.

17.

The cost-effectiveness of the English smoking treatment services: evidence from practice.

Godfrey C, Parrott S, Coleman T, Pound E.

Addiction. 2005 Apr;100 Suppl 2:70-83.

PMID:
15844290
18.

Barriers to generalizability of health economic evaluations in Latin America and the Caribbean region.

Augustovski F, Iglesias C, Manca A, Drummond M, Rubinstein A, Martí SG.

Pharmacoeconomics. 2009;27(11):919-29. doi: 10.2165/11313670-000000000-00000. Review.

PMID:
19888792
19.

Population-based versus high-risk strategies for the prevention of cardiovascular diseases in low- and middle-income countries.

Babu RB, Alam M, Helis E, Fodor JG.

Indian Heart J. 2012 Sep-Oct;64(5):439-43. doi: 10.1016/j.ihj.2012.08.001. Epub 2012 Aug 27.

20.

Cost-effectiveness of using prognostic information to select women with breast cancer for adjuvant systemic therapy.

Williams C, Brunskill S, Altman D, Briggs A, Campbell H, Clarke M, Glanville J, Gray A, Harris A, Johnston K, Lodge M.

Health Technol Assess. 2006 Sep;10(34):iii-iv, ix-xi, 1-204. Review.

Items per page

Supplemental Content

Write to the Help Desk